ES2106185T3 - 3-carboxiesteroides 17-beta-sustituidos no saturados. - Google Patents
3-carboxiesteroides 17-beta-sustituidos no saturados.Info
- Publication number
- ES2106185T3 ES2106185T3 ES92910992T ES92910992T ES2106185T3 ES 2106185 T3 ES2106185 T3 ES 2106185T3 ES 92910992 T ES92910992 T ES 92910992T ES 92910992 T ES92910992 T ES 92910992T ES 2106185 T3 ES2106185 T3 ES 2106185T3
- Authority
- ES
- Spain
- Prior art keywords
- group
- alkyl group
- hydrogen
- cycloalkyl
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Ceramic Products (AREA)
- Dental Preparations (AREA)
- Details Of Garments (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A INHIBIDORES DE LA 5OREDUCTASA ESTEROIDICOS QUE TIENE LA FORMULA (I) EN DONDE Y ES OXIGENO O AZUFRE; R ES UN GRUPO: A) -OR4, EN DONDE R4 ES HIDROGENO O UN GRUPO ALQUILO C1-C6; B) (1) EN DONDE CADA R5 Y R6 ES, INDEPENDIENTEMENTE, HIDROGENO O UN GRUPO ALQUILO C1-C6; C) (2) EN DONDE R7 ES HIDROGENO O UN GRUPO ALQUILO C1-C6 Y W ES UN GRUPO: (I) (3), EN DONDE R8 ES UN GRUPO ALQUILO C1-C6, UN GRUPO CICLOALQUILO C5-C6, UN GRUPO CICLOALQUILALQUILO C6-C9, UN GRUPO FENILO O UN GRUPO BENCILO; O (II) (4), EN DONDE R9 ES UN GRUPO ALQUILO C1-C6 O UN GRUPO CICLOALQUILO C5-C6; O (III) (5), EN DONDE R5 Y R6 SON COMO SE HAN DEFINIDO ARRIBA; (D) (6), EN DONDE CADA R10 Y R11 ES, INDEPENDIENTEMENTE, HIDROGENO O UN GRUPO ALQUILO C1-C6 QUE, TOMADOS JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN ENLAZADOS, FORMAN UN ANILLO HETEROMONOCICLICO SATURADO PENTATOMICO O HEXATOMICO QUE OPCIONALMENTE CONTIENE AL MENOS UN HETEROATOMO ADICIONAL SELECCIONADO DEL OXIGENO Y DEL NITROGENO Y N ES UN ENTERO DE 2 A 4; R1 ES HIDROGENO, UN GRUPO ALQUILO C1C6, UN GRUPO CICLOALQUILO C5-C6, UN GRUPO CICLOALQUILALQUILO C6C9 O UN GRUPO ARILO; CADA R2 Y R3 SE SELECCIONA, INDEPENDIENTEMENTE, DEL GRUPO QUE CONSISTE EN HIDROGENO, ALQUILO C1-C6, CICLOALQUILO C5-C6, CICLOALQUILALQUILO C6-C9 O ARILO O R2 Y R3, TOMADOS JUNTO CON EL ATOMO DE NITROGENO AL QUE SE ENCUENTRAN ENLAZADOS, FORMAN UN ANILLO HETEROMONOCICLICO SATURADO PENTATOMICO O HEXATOMICO QUE OPCIONALMENTE CONTIENE AL MENOS UN HETEROATOMO ADICIONAL SELECCIONADO DEL OXIGENO Y DEL NITROGENO Y EL SIMBOLO DE RAYA CONTINUA CON RAYAS DISCONTINUAS ENCIMA REPRESENTA UN ENLACE DOBLE O SENCILLO QUE, CUANDO ES DOBLE, EL HIDROGENO DE LA POSICION 5O NO EXISTE Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. ANTE LA ACTIVIDAD INHIBIDORA DE LA 5O-REDUCTASA, LOS COMPUESTOS DE LA INVENCION PUEDEN SER UTILES PARA EL TRATAMIENTO DE CONDICIONES ANDROGENODEPENDIENTES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI911432A IT1259419B (it) | 1991-05-24 | 1991-05-24 | Steroidi 3-carbossi 17b - sostituiti insaturi utili come inibitori della testosterone 5 a reduttasi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2106185T3 true ES2106185T3 (es) | 1997-11-01 |
Family
ID=11359980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92910992T Expired - Lifetime ES2106185T3 (es) | 1991-05-24 | 1992-05-22 | 3-carboxiesteroides 17-beta-sustituidos no saturados. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5212166A (es) |
| EP (2) | EP0517047A1 (es) |
| JP (1) | JP3226919B2 (es) |
| CN (1) | CN1035055C (es) |
| AT (1) | ATE155792T1 (es) |
| AU (1) | AU655280B2 (es) |
| CA (1) | CA2087953A1 (es) |
| CZ (1) | CZ281309B6 (es) |
| DE (1) | DE69221074T2 (es) |
| DK (1) | DK0540717T3 (es) |
| ES (1) | ES2106185T3 (es) |
| FI (1) | FI930277A0 (es) |
| HU (1) | HUT64083A (es) |
| ID (1) | ID954B (es) |
| IE (1) | IE921634A1 (es) |
| IL (1) | IL101947A (es) |
| IT (1) | IT1259419B (es) |
| MX (1) | MX9202438A (es) |
| MY (1) | MY131089A (es) |
| NO (1) | NO930244L (es) |
| NZ (1) | NZ242850A (es) |
| RU (1) | RU2104283C1 (es) |
| TW (1) | TW213467B (es) |
| WO (1) | WO1992020700A1 (es) |
| YU (1) | YU52992A (es) |
| ZA (1) | ZA923758B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ252866A (en) * | 1992-04-30 | 1996-09-25 | Smithkline Beecham Corp | 17-acyl-estra-1,3,5(10)-triene-3-carboxylic acids; precursors |
| US5683995A (en) * | 1992-11-18 | 1997-11-04 | Smithkline Beecham Corporation | 17 substituted acyl-3-carboxy 3,5-diene steroidals as α-reductase inhibitors |
| US5641765A (en) * | 1992-11-18 | 1997-06-24 | Smithkline Beecham Corporation | 17-αand 17-βsubstituted acyl-3-carboxy-3,5-dienes and use in inhibiting 5-α-reductase |
| ATE227122T1 (de) * | 1993-09-03 | 2002-11-15 | Smithkline Beecham Corp | Stabilisierte tablettenformulierung |
| GB9324371D0 (en) * | 1993-11-26 | 1994-01-12 | Erba Carlo Spa | Side chain fluoro substituted 3-carboxysteroids |
| US5430157A (en) * | 1993-12-13 | 1995-07-04 | Eli Lilly And Company | Reduced phenanthrenes |
| GB9402041D0 (en) * | 1994-02-03 | 1994-03-30 | Smithkline Beecham Corp | Compounds |
| US5714480A (en) * | 1994-03-31 | 1998-02-03 | Smithkline Beecham Corporation | Treating cardiovascular disease with steroidal 5-alpha-reductase inhibitors |
| WO1995028413A1 (en) * | 1994-04-15 | 1995-10-26 | Smithkline Beecham Corporation | 17β-SUBSTITUTED 3-CARBOXY STEROIDS THAT INHIBIT 5-α-REDUCTASE |
| GB9415183D0 (en) * | 1994-07-28 | 1994-09-21 | Erba Carlo Spa | 3-carboxysteroids with a fluorinated side-chain |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| DE69942578D1 (de) | 1998-05-22 | 2010-08-26 | Univ R | Bifunktionelle moleküle sowie darauf basierende therapien. |
| EP3827747A1 (en) | 2005-04-28 | 2021-06-02 | Otsuka Pharmaceutical Co., Ltd. | Pharma-informatics system |
| US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
| NZ616673A (en) | 2009-02-20 | 2014-08-29 | To Bbb Holding B V | Glutathione-based drug delivery system |
| ES2942923T3 (es) | 2009-05-06 | 2023-06-07 | Laboratory Skin Care Inc | Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041433A (en) * | 1987-04-29 | 1991-08-20 | Smithkline Beecham Corporation | 11-keto or hydroxy 3,5-diene steroids as inhibitors of steriod 5-α-reductase |
| US4910226A (en) * | 1987-04-29 | 1990-03-20 | Smithkline Beckman Corporation | Steroid 5-alpha-reductase inhibitors |
| US5032586A (en) * | 1989-08-24 | 1991-07-16 | Smithkline Beecham Corporation | 7-keto or hydroxy 3,5-diene steroids as inhibitors of steroid 5-alpha reductase |
| US5091380A (en) * | 1990-06-28 | 1992-02-25 | Merck & Co., Inc. | N-monosubstituted adamantyl/norbornanyl 17β-carbamides of 3-carboxy-androst-3,5-dienes as testosterone 5α-reductase inhibitors |
| DK0567271T3 (da) * | 1992-04-20 | 1998-02-16 | Sankyo Co | Steroidderivater til behandling af prostatahypertrofi, fremgangsmåde til fremstilling heraf og anvendelser heraf |
-
1991
- 1991-05-24 IT ITMI911432A patent/IT1259419B/it active IP Right Grant
-
1992
- 1992-05-20 YU YU52992A patent/YU52992A/sh unknown
- 1992-05-20 MY MYPI92000863A patent/MY131089A/en unknown
- 1992-05-21 IL IL10194792A patent/IL101947A/en active IP Right Grant
- 1992-05-21 US US07/886,574 patent/US5212166A/en not_active Expired - Lifetime
- 1992-05-21 NZ NZ242850A patent/NZ242850A/en unknown
- 1992-05-22 ES ES92910992T patent/ES2106185T3/es not_active Expired - Lifetime
- 1992-05-22 JP JP50978992A patent/JP3226919B2/ja not_active Expired - Fee Related
- 1992-05-22 ZA ZA923758A patent/ZA923758B/xx unknown
- 1992-05-22 RU RU93004939A patent/RU2104283C1/ru active
- 1992-05-22 WO PCT/EP1992/001153 patent/WO1992020700A1/en active IP Right Grant
- 1992-05-22 AT AT92910992T patent/ATE155792T1/de active
- 1992-05-22 DE DE69221074T patent/DE69221074T2/de not_active Expired - Fee Related
- 1992-05-22 AU AU17781/92A patent/AU655280B2/en not_active Ceased
- 1992-05-22 HU HU9300176A patent/HUT64083A/hu unknown
- 1992-05-22 EP EP92108670A patent/EP0517047A1/en active Pending
- 1992-05-22 ID IDP308292A patent/ID954B/id unknown
- 1992-05-22 DK DK92910992.4T patent/DK0540717T3/da active
- 1992-05-22 EP EP92910992A patent/EP0540717B1/en not_active Expired - Lifetime
- 1992-05-22 TW TW081104019A patent/TW213467B/zh active
- 1992-05-22 MX MX9202438A patent/MX9202438A/es unknown
- 1992-05-22 CZ CZ93265A patent/CZ281309B6/cs unknown
- 1992-05-22 CA CA002087953A patent/CA2087953A1/en not_active Abandoned
- 1992-05-23 CN CN92103919A patent/CN1035055C/zh not_active Expired - Fee Related
- 1992-07-01 IE IE163492A patent/IE921634A1/en unknown
-
1993
- 1993-01-22 FI FI930277A patent/FI930277A0/fi not_active Application Discontinuation
- 1993-01-25 NO NO93930244A patent/NO930244L/no unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2106185T3 (es) | 3-carboxiesteroides 17-beta-sustituidos no saturados. | |
| ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
| SV2003000876A (es) | Quinazolinas como inhibidores de mmp-13 | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| ECSP034475A (es) | Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1 | |
| BRPI0515133A (pt) | derivados de uréia como bloqueadores do canal de cálcio | |
| CO4950563A1 (es) | Nuevos compuestos | |
| ES2127919T3 (es) | 4-amino-piridinas, procedimiento para su preparacion, asi como medicamentos que contienen estos compuestos. | |
| AR012032A1 (es) | Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion | |
| ES2059804T3 (es) | Procedimiento de preparacion de eteres de oxima de propenona. | |
| CO5601020A2 (es) | Compuestos ox-azabiciclicos | |
| AR241422A1 (es) | Procedimiento para la preparacion de derivados de difenil(metil-etil-0 etenil) piperidinas. | |
| CO5550494A2 (es) | Derivados de diamina, proceso para producir los derivados de diamina, y fungicidas que contienen los derivados de diamina como ingrediente activo | |
| CO4910142A1 (es) | Compuestos de furano nitrona | |
| ES2063815T3 (es) | 2-alquil-3-benzoilbenzofuranos y composiciones farmaceuticas que los contienen. | |
| AR029618A1 (es) | Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos | |
| ES2029879T3 (es) | Procedimiento para producir derivados de aminas sustituidas. | |
| ES2138434T3 (es) | Compuesto fluoropropeno, un insecticida que lo contiene, y un compuesto intermediario para su preparacion. | |
| AR007690A1 (es) | Sales de complejos anionicos de ru (iii) como agentes antimetastasicos y antineoplasicos, procedimiento para la preparacion y usos de dichas sales, y composiciones farmaceuticas que las contienen. | |
| ES2087474T3 (es) | Derivados de aril-3 oxazolidinona, procedimiento de preparacion y aplicacion terapeutica de los mismos. | |
| AR043714A1 (es) | Aductos en base a compuestos ciclicos y su utilizacion como agentes para curtir y conservantes | |
| ES306767A1 (es) | Procedimiento para la preparacion de nuevos derivados basicos de tiepina y oxepina. | |
| AR046763A1 (es) | Compuestos de haloalqueno, proceso para su produccion y pesticidas que los contienen | |
| ES2081111T3 (es) | Derivados de n-hidroxiurea que inhiben la lipoxigenasa. | |
| CO4230083A1 (es) | Novedosos carbomatos y ureas como modificaciones a la resis- tencia a multiples drogas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 540717 Country of ref document: ES |